Submissions for variant NM_000257.4(MYH7):c.2155C>T (p.Arg719Trp)

gnomAD frequency: 0.00001  dbSNP: rs121913637

Total submissions: 18

Submitter	RCV	SCV	Clinical significance	Condition	Last evaluated	Review status	Method	Comment
ClinGen Cardiomyopathy Variant Curation Expert Panel	RCV000758071	SCV000564421	pathogenic	Hypertrophic cardiomyopathy	2016-12-15	reviewed by expert panel	curation	The c.2155C>T (p.Arg719Trp) variant in MYH7 has been reported in >20 individuals with hypertrophic cardiomyopathy (PS4; PMID:9829907; PMID:8282798; PMID:9822100; PMID:12974739; PMID:22429680; PMID:23816408; PMID:12707239; PMID:19645038; PMID:27532257; SHaRe consortium, PMID: 30297972; Partners LMM ClinVar SCV000059419.5 ), including 1 de novo occurrence (PS2; 10957787). This variant was found to segregate with disease in 8 affected family members (PP1_Strong; PMID:9829907; PMID:8282798; PMID:9822100; PMID:12974739; SHaRe consortium, PMID: 30297972). A mouse model indicates that this variant disrupts the function of MYH7 and leads to a phenotype consistent with HCM (PS3: PMID:24829265). This variant was absent from large population studies (PM2; http://exac.broadinstitute.org). This variant lies in the head region of the protein (aa 181-937) and missense variants in this region are statistically more likely to be disease-associated (PM1; PMID:27532257). Computational prediction tools and conservation analysis suggest that this variant may impact the protein (PP3). A different pathogenic missense variant has been previously identified at this codon which may indicate that this residue is critical to the function of the protein (PM5; c.2156G>A p.Arg719Gln - Variation ID 14107). In summary, this variant meets criteria to be classified as pathogenic for hypertrophic cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (PMID:29300372): PS2; PS3; PS4; PP1_ Strong; PM1; PM2; PM5; PP3
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine	RCV000758071	SCV000059419	pathogenic	Hypertrophic cardiomyopathy	2019-02-22	criteria provided, single submitter	clinical testing	The p.Arg719Trp variant in MYH7 has been identified in >30 individuals with HCM (Treger 1965, Hejtmancik 1991, Anan 1994, Greve 1994, Jeschke 1998, Jääskeläinen 1998, Richard 2003, Jääskeläinen 2004, Poutanen 2006, Wang 2009, Santos 2012, Meyer 2013, Walsh 2017, Kelly 2018). In addition, it segregated with disease in >20 affected relatives from multiple families (Hejtmancik 1991, Anan 1994, Wang 2009, Guo 2017, LMM data) and was reported to have occurred de novo in 2 individuals (Greve 1994, Jeschke 1998). It has also been identified in 1/15430 European chromosomes by gnomAD (https://gnomad.broadinstitute.org). In vitro functional studies support an impact on protein function (Yamashita 2000, Kohler 2002, Seebohm 2009, Tripathi 2011). Other variants involving this codon, p.Arg719Gln and p.Arg719Pro, have also been associated with HCM. Of note, this variant lies in the head region of the protein. Missense variants in this region have been reported and statistically indicated to be more likely to cause disease (Walsh 2016). This variant was classified as pathogenic on 12/15/16 by the ClinGen-approved Inherited Cardiomyopathy Expert Panel (Variation ID 14104). In summary, this variant meets criteria to be classified as pathogenic for autosomal dominant HCM. ACMG/AMP Criteria applied: PS4, PP1_Strong, PS2, PS3_Moderate, PM1, PM2, PM5, PP3.
GeneDx	RCV000158512	SCV000208447	pathogenic	not provided	2021-11-24	criteria provided, single submitter	clinical testing	Not observed at a significant frequency in large population cohorts (Lek et al., 2016); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Published functional studies demonstrate increased myosin activity, reduced calcium sensitivity, and increased muscle fiber stiffness (Kohler et al., 2002; Adhikari et al., 2019); This variant is associated with the following publications: (PMID: 27247418, 16504640, 10882745, 8282798, 28166811, 28138913, 7874131, 29907873, 19651039, 9544842, 9822100, 21769673, 25346696, 20624503, 21310275, 23816408, 27532257, 29300372, 19645038, 27082122, 29497013, 29386531, 28420666, 29101517, 28296734, 24510615, 29029073, 29343710, 11904418, 24829265, 30775854, 31737537, 31213605, 32612965, 33673806, 32746448, 32894683)
Eurofins Ntd Llc (ga)	RCV000158512	SCV000226727	pathogenic	not provided	2015-04-03	criteria provided, single submitter	clinical testing
Ambry Genetics	RCV000241836	SCV000318468	pathogenic	Cardiovascular phenotype	2021-07-19	criteria provided, single submitter	clinical testing	The p.R719W pathogenic mutation (also known as c.2155C>T), located in coding exon 17 of the MYH7 gene, results from a C to T substitution at nucleotide position 2155. The arginine at codon 719 is replaced by tryptophan, an amino acid with dissimilar properties. This alteration is located in the myosin head domain, which contains a statistically significant clustering of pathogenic missense variants (Homburger JR et al. Proc Natl Acad Sci U S A, 2016 06;113:6701-6; Walsh R et al. Genet Med, 2017 02;19:192-203; Ambry internal data). This alteration has been described in a number of hypertrophic cardiomyopathy (HCM) cohorts, often characterized by significant hypertrophy and an early age of onset, and has been shown to segregate with disease in several families (Anan et al. J Clin Invest. 1994; 93:280; Zhao Y et al. Int. J. Mol. Med., 2016 Jun;37:1511-20; Ingles J et al. Circ Cardiovasc Genet, 2017 Apr;10:[Epub ahead of print]; Zhang L et al. Front Pediatr, 2020 Jun;8:312). Additionally, this alteration was confirmed to be a de novo occurrence in a child with HCM (Jeschke B et al. Hum Genet. 1998;102:299-304). In functional in vitro analyses, this alteration has demonstrated increased muscle fiber stiffness and generation of force resulting from reduced elastic distortion of the myosin head during contraction, thus suggesting disruption of myosin cross-bridge function (Seebohm B et al. Biophys J. 2009;97:806-24). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation.
Phosphorus, Inc.	RCV000015160	SCV000679782	pathogenic	Hypertrophic cardiomyopathy 1	2017-08-01	criteria provided, single submitter	clinical testing
Blueprint Genetics	RCV000158512	SCV000927157	pathogenic	not provided	2017-02-18	criteria provided, single submitter	clinical testing
Invitae	RCV000758071	SCV000960592	pathogenic	Hypertrophic cardiomyopathy	2024-01-24	criteria provided, single submitter	clinical testing	This sequence change replaces arginine, which is basic and polar, with tryptophan, which is neutral and slightly polar, at codon 719 of the MYH7 protein (p.Arg719Trp). This variant is present in population databases (rs121913637, gnomAD 0.007%). This missense change has been observed in individual(s) with hypertrophic cardiomyopathy (PMID: 8282798, 9544842, 9822100, 11904418, 12707239, 16504640, 19651039, 21769673). In at least one individual the variant was observed to be de novo. It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 14104). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt MYH7 protein function with a positive predictive value of 95%. Experimental studies have shown that this missense change affects MYH7 function (PMID: 10882745, 11904418, 19651039). This variant is found within a region of MYH7 between codons 181 and 937 that contains the majority of the myosin head domain. Missense variants in this region have been shown to be significantly overrepresented in individuals with hypertrophic cardiomyopathy (PMID: 27532257). For these reasons, this variant has been classified as Pathogenic.
Agnes Ginges Centre for Molecular Cardiology, Centenary Institute	RCV000758071	SCV001156298	pathogenic	Hypertrophic cardiomyopathy	2018-09-27	criteria provided, single submitter	research	This variant has been identified in 3 HCM probands by our research program. For further information please feel free to contact us.
CHEO Genetics Diagnostic Laboratory, Children's Hospital of Eastern Ontario	RCV001170501	SCV001333084	pathogenic	Cardiomyopathy	2023-01-27	criteria provided, single submitter	clinical testing
Women's Health and Genetics/Laboratory Corporation of America, LabCorp	RCV001194067	SCV001363323	pathogenic	Primary familial hypertrophic cardiomyopathy	2019-09-24	criteria provided, single submitter	clinical testing	Variant summary: MYH7 c.2155C>T (p.Arg719Trp) results in a non-conservative amino acid change located in the Myosin head, motor domain (IPR001609) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 251466 control chromosomes (gnomAD). c.2155C>T has been reported in the literature in multiple individuals affected with Hypertrophic Cardiomyopathy, with evidence of co-segregation with disease in multiple families and an observed association with high risk for premature death (e.g. Abchee_1997, Anan_1994, Kelly_2018, Poutanen_2006, Walsh_2017). These data indicate that the variant is very likely to be associated with disease. Nonrandom mutation cluster analysis revealed that rare MYH7 missense variants located between residues 181 and 937 have a statistically increased likelihood of being disease-associated (Walsh_2017). Experimental evidence evaluating an impact on protein function demonstrated that the variant significantly increased stiffness and force generation of the individual mutated myosin heads, resulting in reduced elastic distortion of the mutated myosin heads during isometric force generation (Seebohm_2009). Eight ClinVar submitters including an expert panel (ClinGen Inherited Cardiomyopathy Variant Curation Expert Panel) (evaluation after 2014) cite the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.
Molecular Diagnostic Laboratory for Inherited Cardiovascular Disease, Montreal Heart Institute	RCV000015160	SCV001433414	pathogenic	Hypertrophic cardiomyopathy 1	2019-04-16	criteria provided, single submitter	clinical testing
KTest Genetics, KTest	RCV001594372	SCV001499969	pathogenic	Dilated cardiomyopathy 1S		criteria provided, single submitter	clinical testing
Fulgent Genetics, Fulgent Genetics	RCV002496366	SCV002813820	pathogenic	Hypertrophic cardiomyopathy 1; Myopathy, myosin storage, autosomal recessive; Myosin storage myopathy; Congenital myopathy with fiber type disproportion; Dilated cardiomyopathy 1S; MYH7-related skeletal myopathy	2021-11-15	criteria provided, single submitter	clinical testing
OMIM	RCV000015160	SCV000035417	pathogenic	Hypertrophic cardiomyopathy 1	1998-03-01	no assertion criteria provided	literature only
Stanford Center for Inherited Cardiovascular Disease, Stanford University	RCV000158512	SCV000280311	pathogenic	not provided	2013-12-10	no assertion criteria provided	clinical testing	Note this variant was found in clinical genetic testing performed by one or more labs who may also submit to ClinVar. Thus any internal case data may overlap with the internal case data of other labs. The interpretation reviewed below is that of the Stanford Center for Inherited Cardiovascular Disease. This variant has been reported in at least 17 unrelated individuals with HCM (including the two patients in our center) with strong segregation data. Of note, there is data suggesting this variant is associated with a more severe phenotype and high penetrance. In our center we have seen the variant in two patients: a woman diagnosed with HCM at 14 years of age and a man diagnosed with HCM at 29 years of age. The variant was first reported by Greve et al (1994). Unfortunately that report is not available, though the title suggests the variant was de novo. The same group reported four unrelated families with p.Arg719Trp (Anan et al 1994). The authors note that all individuals with HCM in these three kindreds carried the variant. They don’t specify how many individuals were genotyped, though it seems that at least 9 were tested from one family and at least 12 in another, providing very strong segregation data. Jeschke et al (1998) reported a case of childhood-onset HCM and arrest with p.Arg719Trp, which arose de novo, and an additional MYH7 variant inherited from the unaffected mother (p.Met349Thr) (also reported in Dohlemann et al 2000). Paternity was confirmed. While maternity was not formally assesed, it is highly likely to be as reported given maternal inheritance of p.Met349Thr. Jaaskelainen et al (1998) observed the variant in three affected family members from their Finnish cohort. The proband’s mother did have some hypertrophy but was negative for the variant. Poutanen et al (2006) reported two children from the same family with p.Arg719Trp who both had wall thickness at the upper limits of normal, diastolic dysfunction, and pathological Q waves. Richard et al (2003) observed the variant in one individual in their French HCM cohort. Erdmann et al (2003) reported the variant segregating with HCM in two affected members of one family from their German cohort. Frisso et al (2009) observed the variant in three unrelated individuals from their Italian cohort. Santos et al (2012) observed this variant in one individual in their Portuguese cohort. GeneDx reports that p.Arg719Trp was observed in multiple additional unrelated individuals tested for HCM. This is a non-conservative amino acid change with a polar, positive Arginine replaced with a non polar, neutral Tryptophan. Mutationtaster and PolyPhen2 both predict the variant to be damaging. Arginine is conserved at this position across mammals. Other variants at the same codon (p.Arg719Gln (which we consider likely disease causing), p.Arg719Pro) and nearby codons (p.Gly716Arg, p.Arg721Lys, p.Arg712Leu, p.Gly716Arg, p.Arg723Cys, p.Arg723Gly, and p.Ala728Val have been reported in association with HCM (Harvard Sarcomere Protein Gene Mutation Database). Seebohm B et al (2009) demonstrated that the variant could interfere with myosin cross bridge function during contraction. Kohler et al (2002) observed an increase in force generation and fiber stiffness of muscle fibers with p.Arg719Trp and suggested that the cross-bridges were more resistant to elastic distortion. Anan et al (1994) suggested that this variant may be correlated with a particularly severe phenotype since the four families they studied with the variant had a particularly high frequency of disease-related deaths. Many of the initial genotype-phenotype correlations based on a handful of cases have since been called into question by the observation of mild disease in other families with the same variant, suggesting the initial observations may have been due to ascertainment bias. However, a recent paper from the same group found significantly earlier age of onset and age of first cardiac event in carriers of p.Arg719Trp as compared to carriers of MYBPC3 truncating variants or p.Arg502Trp in MYBPC3 (the most prevalent HCM-causing variant) (Saltzman et al 2010). All carriers had manifest disease by 30 years of age. It is unclear though, how many p.Arg719Trp carriers were included or how they were ascertained. Unfortunately many of the case reports reviewed above do not provide detailed data on severity, progression, or outcome. The variant was not observed in ~7000 published controls and publically available general population samples. GeneDx did not report internal control data. The variant is not listed in 1000 Genomes. There is no variation at codon 719 currently listed in the NHLBI Exome Sequencing Project dataset, which includes variant calls on approximately 6500 Caucasian and African American individuals (as of May 2014). Richard et al (2003) did not observe the variant in 100 controls. Frisso et al (2009) did not observe the variant in 200 controls with normal ECGs. Santos et al (2012) did not observe the variant in 100 healthy individuals.
Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen	RCV000158512	SCV001742585	pathogenic	not provided		no assertion criteria provided	clinical testing
Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center	RCV000158512	SCV001972737	pathogenic	not provided		no assertion criteria provided	clinical testing